IP Library Granted Patent US 10,913,943
Granted Patent B2
US 10,913,943 · App. 16/190,229 · Granted Feb 9, 2021

Enhanced stem cell therapy and stem cell production through the administration of low level light energy

Inventors: Jackson Streeter (Newberry, FL); Luis De Taboada (Carlsbad, CA)
Assignee: Pthera LLC
C12N13/00A61N5/0613A61N5/0622A61N2005/063A61N2005/067A61N2005/0647A61N2005/0659
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,913,943
App. No.
16/190,229
Granted
Feb 9, 2021
Kind
B2
Abstract

Methods of enhancing stem cell therapy through the administration of low level light energy are provided in several embodiments. Some embodiments comprise irradiating stem cells before or after implantation at a target tissue having loss of function due to damage or disease, with a resultant increase in the efficacy of the cell therapy. In some embodiments, light energy enhances one or more of the viability, proliferation, migration or engraftment of the stem cells, thereby enhancing the therapeutic effects of the irradiated cells during cell therapy.

Claims (15)

1. A method for enhancing the efficacy of stem cell therapy in a mammal comprising:

identifying a mammal having neural tissue with an impaired function;

administering one or more stem cells to said tissue;

providing a low level light therapy (LLLT) device, wherein said LLLT device has a light emitting surface that emits light energy; and

delivering light energy to said tissue,

wherein the light energy has a wavelength between 630 nm and 904 nm, and

wherein the light energy enhances one or more of an engraftment and migration of said administered stem cells.

2. The method of claim 1 , wherein the impaired function is due to degenerative neural disease.

3. The method of claim 2 , wherein the degenerative neural disease is selected form the group consisting of Parkinson's disease, Alzheimer's disease, Huntington's disease, dopaminergic impairment, and dementia.

4. The method of claim 1 , wherein the impaired neural function is a result of injury to a neuron.

5. The method of claim 1 , further comprising delivering said light energy to said stem cells prior to administering said stem cells to said tissue.

6. The method of claim 1 , wherein delivering said light energy to said tissue comprises delivering said light energy to said stem cells after administering said stem cells to said tissue.

7. The method of claim 1 , wherein the administered stem cells comprise mesenchymal stem cells.

8. The method of claim 7 , wherein said mesenchymal stem cells are allogeneic to said mammal.

9. The method of claim 1 , wherein said light energy is pulsed.

Assignments (5)
CORRECTIVE ASSIGNMENT TO CORRECT THE TYPO IN THE ASSIGNEE NAME FROM PTHERA, LLC TO PTHERA LLC PREVIOUSLY RECORDED ON REEL 049461 FRAME 0150. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Sep 15, 2020
From: DE TABOADA, LUIS H.
To: PTHERA LLC
Reel/Frame 053782/0558 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2019
From: DE TABOADA, LUIS; STREETER, JACKSON
To: PHOTOTHERA, INC.
Reel/Frame 049460/0606 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2019
From: PHOTOTHERA, INC.
To: PHOTOTHERA IP HOLDINGS, INC.
Reel/Frame 049460/0846 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2019
From: ADVANCED PHOTONICS SOLUTIONS, INC.
To: DE TABOADA, LUIS
Reel/Frame 049461/0005 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2019
From: DE TABOADA, LUIS
To: PTHERA, LLC
Reel/Frame 049461/0150 →
Cited By (4)
US 12,290,701 US 12,521,567 US 12,582,836 US 12,714,876